Skip to content

Sympathetic Activation in Obesity

Sympathetic Activation in Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04946552
Enrollment
5
Registered
2021-07-01
Start date
2021-11-23
Completion date
2022-09-30
Last updated
2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Healthy

Brief summary

The primary objective of this study is to determine whether sympathetic nervous system (SNS) activity in white adipose tissue (WAT) and brown adipose tissue (BAT), skeletal muscle and brain is altered in individuals with obesity in comparison to individuals with normal weight. Simultaneous multi-organ SNS activation will be obtained with a radiotracer for norepinephrine transporter (NET) for whole-body Positron Emission Tomography (PET) imaging and microneurography (peroneal muscle SNS activity). The secondary objectives of this study are: 1) to evaluate whether gender differences affect peripheral SNS in healthy normal weight and obese men and women in adipose tissue (WAT and BAT) and muscle (resting/fasting); 2) To investigate the relationship between peripheral and central SNS activity in obesity, by correlating SNS activity in peripheral tissues (WAT, BAT, and muscle) and brain; and 3) To investigate NET CNS and peripheral SNS activity before and after a high carbohydrate mixed meal in lean and obese men and women.

Interventions

DIAGNOSTIC_TESTPET Scan

Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\ 20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.

DIETARY_SUPPLEMENTMixed Meal Test

High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \ 16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.

DIAGNOSTIC_TESTMuscle sympathetic nerve activity (MSNA)

Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.

DIAGNOSTIC_TESTOral Glucose Tolerance Test

Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.

OTHERBody Composition, Percent Body Fat & Percent Body Water (Tanita scale)

will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.

DIAGNOSTIC_TESTCT Scan

A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.

OTHERBody Composition, Percent Body Fat & Percent Body Water (DXA Scan)

For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age 18-45 years 4. In good general health as evidenced by medical history and lean (BMI 18.5-24.9 kg/m2) or non-diabetic obese (BMI 30-50 kg/m2) with a fasting plasma glucose (FPG) \<100 mg/dL and a hemoglobin A1c \<5.7%.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study: 1. Hypertension 2. Cardiac or pulmonary disease, 3. Known history of Type 1 or Type 2 diabetes 4. Hepatic disease, swallowing and gastrointestinal disorders 5. Current use of anti-obesity medications, supplements and/or anti-hyperglycemic medications 6. Neurological injury or illness, and psychiatric medications 7. Women who are pregnant or lactating 8. Subjects who suffer from claustrophobia 9. Subjects who have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study 10. Radiation works or participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits. 11. Subjects with history of IV drug use which would prevent venous access for PET tracer injection 12. Severe motor problems that prevent the subject from lying still for PET and MR imaging 13. Subjects who complain of chronic pain 14. Blood donation within 8 weeks of the study

Design outcomes

Primary

MeasureTime frameDescription
Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System120 minutesLean individuals with a BMI of 18-25 and obese individuals with a BMI of 30-40 will undergo a PET/CT scan to determine group differences in sympathetic nervous system (SNS) activity in white adipose tissue (WAT), brown adipose tissue (BAT), and deltoid muscle. SNS activity will be determined by using \[11C\]MRB a radiotracer for PET imaging.
Microneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst Frequency30-60 minutesMuscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (mean number of bursts per unit time) to determinate group differences in peroneal MSNA at baseline (fasting) and during MMT.

Secondary

MeasureTime frameDescription
Plasma Glucose2 hoursMeasurement of plasma glucose levels will be obtained at fasting and during the Mixed Meal Test (MMT). The normal range for glucose levels is 70-100 mg/dL.
Insulin Levels2 hoursMeasurement of plasma insulin levels will be obtained at fasting and during the MMT. Insulin levels in the plasma are higher in individuals with obesity. The normal range for insulin is: \< or = 19.6 mcg/dL
C-Peptide2 hoursPlasma samples will be drawn at baseline and throughout the MMT for measurement of C-Peptide. The normal range for C-Peptide is 0.80 - 3.85 ng/mL
Plasma Catecholamines (Epinephrine and Norepinephrine)2 hoursMeasurement of epinephrine and norepinephrine levels in the plasma at fasting and during the MMT. The normal range for epinephrine is 0 to 140 pg/mL (764.3 pmol/L). The normal range for norepinephrine is 70 to 1700 pg/mL (413.8 to 10048.7 pmol/L).
DVR of Norepinephrine Transporter (NET) in the Central Nervous System (CNS)120 minutesRegional quantification of \[11C\]MRB uptake as distribution volume ratio (DVR ) will be used to measure NET in the CNS.
Thyroid Function Tests2 hoursPlasma samples will be drawn at baseline and throughout the mixed meal test (MMT) for measurement of Thyroid Stimulating Hormone (TSH), free T4 (FT4) and total T3 (TT3). The normal range for TSH is : 0.4-4.5 mlU/L, FT4: 0.8-1.8 ng/dL, TT3: 76 - 181 ng/dL.
Electrocardiogram (EKG)- Heart Rate30-60 minutesEKG surface electrodes will be applied to the chest for measurement of heart rate and heart rate variability (QT Interval).
Electrocardiogram (EKG) - RR Interval30-60 minutesEKG surface electrodes will be applied to the chest for measurement of RR interval.
Plasma Free Fatty Acids (FFA)2 hoursPercent of plasma free fatty acids levels will be obtained at fasting and during the Mixed Meal Test (MMT). FFA levels in the plasma are higher in individuals with obesity than individuals with normal weight.
DVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal Test120 minutesMeasurement of peripheral SNS Activity with \[11C\]MRC for PET/CT before (fasting) and after a high carbohydrate mixed meal in individuals with normal weight and obesity.

Countries

United States

Participant flow

Participants by arm

ArmCount
Overall
Presented are baseline characteristics overall as there were only 2 people in a single treatment arm and therefore identifying information could be obtained.
5
Total5

Baseline characteristics

CharacteristicOverall
Age, Continuous32.4 years
STANDARD_DEVIATION 1.2
Body Mass Index (BMI)30.65 kg/m2
STANDARD_DEVIATION 2.5
Diastolic BP67.85 mmHg
STANDARD_DEVIATION 6.6
Insulin Sensitivity Index (ISI) Score using the Matsuda Index2.95 score on a scale
STANDARD_DEVIATION 0.65
Race/Ethnicity, Customized
Hispanic
2 Participants
Race/Ethnicity, Customized
White
3 Participants
Region of Enrollment
United States
5 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
2 Participants
Study Group
Lean Group (BMI 18-25 kg/m2)
3 Participants
Study Group
Obese Group (BMI Greater than 25 kg/m2)
2 Participants
Systolic Blood Pressure (BP)108.85 mmHg
STANDARD_DEVIATION 8.55
Weight68.45 kilograms
STANDARD_DEVIATION 4.2

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 30 / 2
other
Total, other adverse events
0 / 30 / 2
serious
Total, serious adverse events
0 / 30 / 2

Outcome results

Primary

Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System

Lean individuals with a BMI of 18-25 and obese individuals with a BMI of 30-40 will undergo a PET/CT scan to determine group differences in sympathetic nervous system (SNS) activity in white adipose tissue (WAT), brown adipose tissue (BAT), and deltoid muscle. SNS activity will be determined by using \[11C\]MRB a radiotracer for PET imaging.

Time frame: 120 minutes

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Putamen0.13 DVRStandard Deviation 0.014
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Caudate0.095 DVRStandard Deviation 0.063
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Hypothalamus-0.095 DVRStandard Deviation 0.691
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Locus Ceruleus-1.47 DVRStandard Deviation 1.49
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Thalamus0.295 DVRStandard Deviation 0.205
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Raphe-0.255 DVRStandard Deviation 0.049
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Paracentral Lobule0.045 DVRStandard Deviation 0.587
Individuals With Normal BMIDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemMuscle: Deltoid0.525 DVRStandard Deviation 0.058
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemMuscle: Deltoid0.549 DVRStandard Deviation 0.107
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Putamen-0.025 DVRStandard Deviation 0.12
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Thalamus-0.115 DVRStandard Deviation 0.092
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Caudate-0.03 DVRStandard Deviation 0.028
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Paracentral Lobule-0.055 DVRStandard Deviation 0.191
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Hypothalamus-0.195 DVRStandard Deviation 0.332
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Raphe-0.455 DVRStandard Deviation 0.657
Individuals With ObesityDistribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous SystemBrain: Locus Ceruleus-0.01 DVRStandard Deviation 0.283
Primary

Microneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst Frequency

Muscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (mean number of bursts per unit time) to determinate group differences in peroneal MSNA at baseline (fasting) and during MMT.

Time frame: 30-60 minutes

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIMicroneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst FrequencyFasting11.18 bursts per minuteStandard Deviation 1.58
Individuals With Normal BMIMicroneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst FrequencyMMT15.63 bursts per minuteStandard Deviation 4.8
Individuals With ObesityMicroneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst FrequencyFasting9.541 bursts per minuteStandard Deviation 0.245
Individuals With ObesityMicroneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst FrequencyMMT11.60 bursts per minuteStandard Deviation 2.61
Secondary

C-Peptide

Plasma samples will be drawn at baseline and throughout the MMT for measurement of C-Peptide. The normal range for C-Peptide is 0.80 - 3.85 ng/mL

Time frame: 2 hours

Population: Data for this outcome was not collected

Secondary

DVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal Test

Measurement of peripheral SNS Activity with \[11C\]MRC for PET/CT before (fasting) and after a high carbohydrate mixed meal in individuals with normal weight and obesity.

Time frame: 120 minutes

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIDVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal TestFasting0.577 DVRStandard Deviation 0.121
Individuals With Normal BMIDVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal TestMMT0.521 DVRStandard Deviation 0.128
Individuals With ObesityDVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal TestFasting0.491 DVRStandard Deviation 0.041
Individuals With ObesityDVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal TestMMT0.559 DVRStandard Deviation 0.061
Secondary

DVR of Norepinephrine Transporter (NET) in the Central Nervous System (CNS)

Regional quantification of \[11C\]MRB uptake as distribution volume ratio (DVR ) will be used to measure NET in the CNS.

Time frame: 120 minutes

ArmMeasureValue (MEAN)Dispersion
Individuals With Normal BMIDVR of Norepinephrine Transporter (NET) in the Central Nervous System (CNS)0.549 DVRStandard Deviation 0.107
Individuals With ObesityDVR of Norepinephrine Transporter (NET) in the Central Nervous System (CNS)0.525 DVRStandard Deviation 0.058
Secondary

Electrocardiogram (EKG)- Heart Rate

EKG surface electrodes will be applied to the chest for measurement of heart rate and heart rate variability (QT Interval).

Time frame: 30-60 minutes

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIElectrocardiogram (EKG)- Heart RateFasting61.8 beats per minuteStandard Deviation 6.47
Individuals With Normal BMIElectrocardiogram (EKG)- Heart RateMMT65.6 beats per minuteStandard Deviation 9.97
Individuals With ObesityElectrocardiogram (EKG)- Heart RateFasting74.2 beats per minuteStandard Deviation 4.06
Individuals With ObesityElectrocardiogram (EKG)- Heart RateMMT71.7 beats per minuteStandard Deviation 5.32
Secondary

Electrocardiogram (EKG) - RR Interval

EKG surface electrodes will be applied to the chest for measurement of RR interval.

Time frame: 30-60 minutes

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIElectrocardiogram (EKG) - RR IntervalFasting0.94 secondsStandard Deviation 0.16
Individuals With Normal BMIElectrocardiogram (EKG) - RR IntervalMMT0.91 secondsStandard Deviation 0.07
Individuals With ObesityElectrocardiogram (EKG) - RR IntervalFasting1.01 secondsStandard Deviation 0.11
Individuals With ObesityElectrocardiogram (EKG) - RR IntervalMMT0.85 secondsStandard Deviation 0.16
Secondary

Insulin Levels

Measurement of plasma insulin levels will be obtained at fasting and during the MMT. Insulin levels in the plasma are higher in individuals with obesity. The normal range for insulin is: \< or = 19.6 mcg/dL

Time frame: 2 hours

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIInsulin LevelsFasting7.07 uU/mLStandard Deviation 0.568
Individuals With Normal BMIInsulin LevelsMMT61.06 uU/mLStandard Deviation 54.3
Individuals With ObesityInsulin LevelsFasting15.55 uU/mLStandard Deviation 0.327
Individuals With ObesityInsulin LevelsMMT78.37 uU/mLStandard Deviation 45.96
Secondary

Plasma Catecholamines (Epinephrine and Norepinephrine)

Measurement of epinephrine and norepinephrine levels in the plasma at fasting and during the MMT. The normal range for epinephrine is 0 to 140 pg/mL (764.3 pmol/L). The normal range for norepinephrine is 70 to 1700 pg/mL (413.8 to 10048.7 pmol/L).

Time frame: 2 hours

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIPlasma Catecholamines (Epinephrine and Norepinephrine)Norepinephrine MMT0.278 mg/mLStandard Deviation 0.109
Individuals With Normal BMIPlasma Catecholamines (Epinephrine and Norepinephrine)Norepinephrine Fasting0.146 mg/mLStandard Deviation 0.0376
Individuals With Normal BMIPlasma Catecholamines (Epinephrine and Norepinephrine)Epinephrine MMT0.0155 mg/mLStandard Deviation 0
Individuals With Normal BMIPlasma Catecholamines (Epinephrine and Norepinephrine)Epinephrine Fasting0.0487 mg/mLStandard Deviation 0.0167
Individuals With ObesityPlasma Catecholamines (Epinephrine and Norepinephrine)Norepinephrine MMT0.162 mg/mLStandard Deviation 0.0779
Individuals With ObesityPlasma Catecholamines (Epinephrine and Norepinephrine)Epinephrine Fasting0.0131 mg/mLStandard Deviation 0.0238
Individuals With ObesityPlasma Catecholamines (Epinephrine and Norepinephrine)Epinephrine MMT0.0136 mg/mLStandard Deviation 0.0138
Individuals With ObesityPlasma Catecholamines (Epinephrine and Norepinephrine)Norepinephrine Fasting0.135 mg/mLStandard Deviation 0.0572
Secondary

Plasma Free Fatty Acids (FFA)

Percent of plasma free fatty acids levels will be obtained at fasting and during the Mixed Meal Test (MMT). FFA levels in the plasma are higher in individuals with obesity than individuals with normal weight.

Time frame: 2 hours

ArmMeasureGroupValue (MEAN)Dispersion
Individuals With Normal BMIPlasma Free Fatty Acids (FFA)Fasting380 percentage of FFAStandard Deviation 42.91
Individuals With Normal BMIPlasma Free Fatty Acids (FFA)MMT419 percentage of FFAStandard Deviation 19.2
Individuals With ObesityPlasma Free Fatty Acids (FFA)Fasting412 percentage of FFAStandard Deviation 37.702
Individuals With ObesityPlasma Free Fatty Acids (FFA)MMT404 percentage of FFAStandard Deviation 35.4
Secondary

Plasma Glucose

Measurement of plasma glucose levels will be obtained at fasting and during the Mixed Meal Test (MMT). The normal range for glucose levels is 70-100 mg/dL.

Time frame: 2 hours

Population: Data for this outcome was not collected

Secondary

Thyroid Function Tests

Plasma samples will be drawn at baseline and throughout the mixed meal test (MMT) for measurement of Thyroid Stimulating Hormone (TSH), free T4 (FT4) and total T3 (TT3). The normal range for TSH is : 0.4-4.5 mlU/L, FT4: 0.8-1.8 ng/dL, TT3: 76 - 181 ng/dL.

Time frame: 2 hours

Population: Data for this outcome was not collected

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026